⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 13, 2024European Journal of Pharmaceutical SciencesOpen Access

Safety, tolerability, and pharmacokinetic of HY0721 in Chinese healthy subjects: A first-in-human randomized, double-blind, placebo-controlled dose escalation phase I study

Mengyu Zhang Runhan Liu Ying Wang Xiaohong Zhu Zhenlei Wang Xiaoyu Li Li Zheng

View Full Paper

Ask AI

Bookmark

Share

Abstract

HY0721 is a novel inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4 (SUR1-TRPM4) for the treatment of acute ischemic stroke. This study aimed to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of single and multiple intravenous administration of HY0721 in Chinese healthy subjects.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e64e7db6db6435875deeaf https://doi.org/10.1016/j.ejps.2024.106832

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese SubjectsRCT · 2023 · 2 citations
2Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjectsHuman Clinical Trial · 2026 · 1 citations
3A Phase I Double‐Blind, Placebo‐Controlled, Single Rising Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of Oral YM934 in Healthy Male VolunteersRCT · 1998 · 3 citations
4Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical TrialHuman Clinical Trial · 2026
5A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid receptor antagonist, in healthy men2024 · 1 citations

More related papers

Pharmacokinetics, pharmacodynamics, safety, and tolerability of hyzetimibe (HS-25) in healthy Chinese subjects2014
Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel, in healthy subjects2021
A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers2021

More from European Journal of Pharmaceutical Sciences

Engineering nanocarriers for PROTAC delivery: liposomes, cyclodextrin aggregates, and albumin-based nanoparticles for ACBI2 and ACBI3Sun,
161Tb radiopharmaceutical therapy as a treatment for RANKL-positive multiple myelomaSat,